Corcept Therapeutics in our Pivotal Point Check: Breakthrough in Cancer Research - ROSELLA Study Success Catapults Stock up Over 100%!
Reading Time: 2 minutes
Ovarian cancer is the fifth leading cause of cancer-related death among women. The ROSELLA study achieved a 30% reduction in the risk of disease progression. Further growth opportunities in the Cushing's syndrome business provide optimism. Corcept Therapeutics is dedicated to the research and development of drugs for the treatment of severe disorders by modulating the effects of the hormone cortisol. The company announced on March 31, 2025, that ROSELLA, the pivotal Phase 3 study of Relacorilant plus nab-paclitaxel in patients...
Read this article now with a free account.
Your benefits:
- Every month, you can read 5 articles from the premium section for free.
- Monthly 2 trial issues of the Trader newspaper for free.
- Create a personal watchlist with an overview of news about your stock.
